KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Alnylam Pharmaceuticals (ALNY) Receivables - Net (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Receivables - Net for 16 consecutive years, with $777.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Net rose 91.85% year-over-year to $777.6 million, compared with a TTM value of $777.6 million through Dec 2025, up 91.85%, and an annual FY2025 reading of $777.6 million, up 91.85% over the prior year.
  • Receivables - Net was $777.6 million for Q4 2025 at Alnylam Pharmaceuticals, down from $964.8 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $964.8 million in Q3 2025 and bottomed at $9.1 million in Q2 2022.
  • Average Receivables - Net over 5 years is $279.5 million, with a median of $220.0 million recorded in 2023.
  • The sharpest move saw Receivables - Net tumbled 78.83% in 2022, then surged 2331.51% in 2023.
  • Year by year, Receivables - Net stood at $73.3 million in 2021, then crashed by 55.86% to $32.3 million in 2022, then surged by 207.88% to $99.6 million in 2023, then surged by 307.03% to $405.3 million in 2024, then surged by 91.85% to $777.6 million in 2025.
  • Business Quant data shows Receivables - Net for ALNY at $777.6 million in Q4 2025, $964.8 million in Q3 2025, and $567.1 million in Q2 2025.